GFP
HAE icon

Gryphon Financial Partners’s Haemonetics HAE Stock Holding History

Gryphon Financial Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-47
Closed -$4K – 441
2018
Q2 		$4K Sell
47
-44
-48% -$3.72K ﹤0.01% 709
2018
Q1 		$7K Buy
91
+13
+17% +$892 ﹤0.01% 604
2017
Q4 		$5K Buy
+78
New +$4.11K ﹤0.01% 741

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Gryphon Financial Partners's HAE Position: Q3 2018 in Review

Gryphon Financial Partners sold out of Haemonetics (HAE) in Q3 2018, closing a stake of 47 shares — an estimated $4K sold.

Gryphon Financial Partners first reported a position in HAE in Q4 2017 and held it in 3 quarters. The position peaked at $7K in Q1 2018. 292 funds tracked by Wall St. Rank hold HAE as of Q3 2018.

  • Gryphon Financial Partners reported no remaining Haemonetics position as of Q3 2018 after selling out during the quarter.
  • Gryphon Financial Partners sold 47 Haemonetics shares in Q3 2018, an estimated $4K.
  • Gryphon Financial Partners first reported a position in Haemonetics in Q4 2017 and held it in 3 quarters.
  • Gryphon Financial Partners's Haemonetics position peaked at $7K in Q1 2018.
  • 292 funds tracked by Wall St. Rank held Haemonetics as of Q3 2018.

Based on Gryphon Financial Partners's 13F filing for Q3 2018, filed 6 Nov 2018.